I think you will find $MCET a more legit porky when this goes from .0016 to .0005 good luck. I'm going to be laughing at everyone still here wishing upon a hope and a prayer averaging down to save face.
7) I got MCET management to have MCET patent attorney David Lewis pay the maintenance fee on Fa N2-4 immortalized Human Hepatocytes Cell Lines on Dec 18, 2020.
1) PAID IN FULL MCET's Patent Maintenance Fee on 12-18-2020 for their Fa2n-4 and Ea1C-35 ImmortalizedHuman Hepatocytes Cell Lines
IMMORTALIZED HEPATOCYTES
PATENT #
7566567
APPLICATION #
10574163
FILING DATE
03/29/2006
ISSUE DATE
07/28/2009
Payment Window Status
WINDOW
11.5 Year
STATUS
Closed
FEES
Paid
Window
First Day to Pay
Surcharge Starts
Last Day to Pay
Status
Fees
Statement
3.5 Year 07/28/2012 01/29/2013 07/29/2013 Closed Paid Statement
7.5 Year 07/28/2016 01/31/2017 07/28/2017 Closed Paid Statement
11.5 Year 07/28/2020 01/29/2021 07/28/2021 Closed Paid Statement
Patent Holder Information
Customer # 87008
Entity Status UNDISCOUNTED
Phone Number (408) 993-1800
Address MultiCell Technologies, Inc.
c/o David Lewis
1250 Aviation Avenue, Suite 200B
San Jose, CA 95110
UNITED STATES
8) Also see next post
9) MCET has employees in at least 3 countries, Brazil, Mexico and the USA.
I can send this to you if needed.
10) If you have any questions or you want to help, you can email me at.
mcetdreamer@gmail.com
11) On Mon, Sep 21, 2020, 4:33 PM Barbara Corbett <mcetinvestor@aol.com> wrote: Hi, again,
I am re-reviewing our correspondence and wondering if you heard back from Mr. Sigmond. I got no email from him.
Belated condolences for your mother's passing.
I see no record of having gotten a twitter message from anyone re MultiCell. I use Twitter only to promote my art/photography.
The MultiCell -Xeno Tech agreement was terminated. I don't know what we can do about them continuing to sell our patented cells.
"MultiCell Takes Control of Cell Marketing Program
Monday February 6, 6:30 am ET PROVIDENCE, R.I.--(BUSINESS WIRE)--Feb. 6, 2006--MultiCell Technologies, Inc. (OTCBB:MCET - News), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, and a leading supplier of non-tumorigenic immortalized human hepatocytes, announced today it had terminated the exclusive license agreement with XenoTech, LLC of Lenexa, Kansas, effective January 31, 2006, for failure to meet minimum royalty obligations.
Under terms of the 2003 agreement, XenoTech was allowed to sell sub-licenses for the propagation of Multicell's immortalized human liver cells ("hepatocytes"). These cells may be used to develop highly predictive, high-throughput drug development assays for drug discovery, lead optimization and pharmacogenomic studies. Industry statistics show, on the average, it now costs almost $1 billion to develop a new drug. Many drugs fail in development because the human liver cannot process toxic aspects of many new drug candidates. MultiCell believes that highly predictive assays such as ones using its hepatocytes could predict potential failures earlier in the development process thus saving pharmaceutical companies millions of dollars in drug development costs. "We believe our immortalized human hepatocytes are ideal products, which help to fill a currently unmet need within the pharmaceutical industry, and that there are no other consistent products available to pharmaceutical companies for predicting the liver toxicity of new drug compounds," Stephen Chang, Ph.D., President of Multicell explained. "We believe that one of MultiCell's greatest strategic advantages is our management team's ability to move quickly to complete transactions as evidenced in the past six months. We plan to take advantage of this strength by taking direct control of the marketing and selling activities for this key product."
About MultiCell Technologies, Inc.MultiCell Technologies, Inc. is a developer of therapeutic products, and a supplier of immortalized human cell lines for drug discovery applications. With its majority-owned subsidiary MultiCell Immunotherapeutics, Inc., MultiCell is working to commercialize new therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases. MultiCell's cellular systems research labs are in Lincoln, RI. MultiCell Immunotherapeutics is located in San Diego, CA. For more information about MultiCell see multicelltech.com. Information on our website is not part of this press release. Caution Regarding Forward-Looking StatementsAny statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding contemplated guidance in the investment and financial markets, evaluation of the company's lead drug candidates, or commencement of clinical trials. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2004, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assumes no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events."
News 
Market Data 
Discover 
